# Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

> **NCT00144209** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 58 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** pramipexole
- **DRUG:** levodopa in combination with benserazide

## Key facts

- **NCT ID:** NCT00144209
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144209, "Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00144209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*